Rezdiffra (Resmetirom) Cost in Iowa: Pricing, Insurance, and Savings Options for 2026

Resmetirom is available under the brand name Rezdiffra as an oral tablet that works by activating thyroid hormone receptor beta (THR-beta). In March 2024, the FDA granted accelerated approval for resmetirom to treat adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) accompanied by moderate to advanced liver fibrosis (stages F2-F3), when combined with diet and exercise modifications. Resmetirom is not approved for early-stage fatty liver disease in the absence of fibrosis and belongs to a distinct drug class from the GLP-1 receptor agonists that are sometimes prescribed off-label to address weight gain in MASH patients.

The most useful framing for an Iowa patient is not "what does Rezdiffra cost" but "which payment pathway applies to my specific coverage situation." Resmetirom's list price is set nationally by the manufacturer and does not vary by state, but what a given Iowa patient actually pays depends on three separate and independently volatile facts: whether their insurer (commercial, Medicaid, or Medicare) has added it to formulary, whether they qualify for the manufacturer copay program, and whether a compounded alternative is even a legally appropriate option for their case. None of those three facts is fixed, and confusing "the drug exists and is approved" with "my plan covers it" is the most common costly mistake.

What is firmly established

• Resmetirom (Rezdiffra) received FDA accelerated approval in March 2024 for MASH with F2-F3 fibrosis, based on surrogate liver-biopsy endpoints from a phase 3 trial. Full approval is conditional on a confirmatory outcomes trial that has not yet reported. You can review the current label and approval history directly on the FDA drug approval database.
• Accelerated approval means the FDA authorized the drug based on a measure believed to predict clinical benefit (fibrosis and NASH-resolution findings on biopsy), not yet on confirmed reductions in cirrhosis, transplant, or death. The FDA explains this distinction on its accelerated approval program page. This is a material uncertainty, not a technicality: payers frequently cite it when limiting coverage.
• Federal law permits state-licensed 503A pharmacies to compound a drug for a named, individual patient with a valid prescription, as described on the FDA's compounding laws and policies page. But 503A compounding is legally restricted to situations of documented clinical need, such as an allergy to an inactive ingredient, a needed strength or dosage form that is not commercially marketed, or a manufacturer shortage. It is not intended as a general substitute for a commercially available FDA-approved product purely to reduce cost, and resmetirom's commercial availability may make blanket "compounded Rezdiffra" marketing legally questionable. Anyone considering this route should ask the prescriber and pharmacy directly what documented clinical justification supports compounding in their case, and can verify a pharmacy's license status through the Iowa Board of Pharmacy.
• Medicare Part D beneficiaries benefit from the Inflation Reduction Act's annual out-of-pocket cap on covered Part D drug spending, a rule described by CMS. Whether resmetirom is on a given Iowa Part D plan's formulary is a separate, plan-specific question that changes plan year to year.
• Manufacturer commercial copay assistance programs, when they exist, generally exclude patients enrolled in any government insurance program (Medicare, Medicaid, TRICARE) because of federal anti-kickback rules. This is a general rule across the specialty drug industry, not specific to resmetirom, and applies in Iowa the same as anywhere else.

What is plausible or reported but needs local, dated verification

The following categories change often and were not independently verified against a live source for this draft. Do not treat any of these as fixed:

• Cash and list price. Manufacturer and patient-facing sources have cited a list price in the range of several thousand dollars per month for Rezdiffra. Exact current pricing, and whether Iowa retail or mail-order pharmacies deviate from list price, should be confirmed directly with the pharmacy or the manufacturer's patient support line before assuming a specific figure.
• Iowa Medicaid coverage status. Whether Rezdiffra sits on the Iowa Medicaid preferred drug list, and under what prior authorization criteria, is a formulary decision that Iowa's Medicaid program can revise at any review cycle. Confirm current status directly with Iowa Medicaid or the Iowa Department of Health and Human Services rather than relying on a prior year's status.
• Commercial insurer prior authorization criteria. Individual Iowa commercial insurers set their own step-therapy and documentation requirements (biopsy versus noninvasive fibrosis testing, trial of vitamin E or pioglitazone first, specialist involvement) and these change without notice. Ask your specific plan's specialty pharmacy or pharmacy benefit manager for the current criteria in writing.
• Manufacturer savings card terms. Eligibility, the covered gap amount, and any annual benefit cap for a Rezdiffra copay card are set by the manufacturer and can change. Confirm current terms through the manufacturer's patient support program before assuming a specific out-of-pocket floor or annual maximum.
• Compounded pricing. Any price quoted by an individual compounding pharmacy is specific to that pharmacy and not representative of a statewide average. Compounded preparations are not FDA-reviewed for safety, purity, or bioequivalence to the branded product, which is a separate concern from price.
• Charitable foundation fund availability. Foundations such as the Patient Access Network Foundation and the HealthWell Foundation open and close disease-specific funds based on available money, and a fund for MASH or liver disease medications may not be open at any given time.

Should you pursue commercial insurance prior authorization first?

For patients with employer-sponsored or marketplace commercial insurance, prior authorization is generally the first and most cost-effective pathway to try, because a covered specialty drug's copay (even on a high specialty tier) is usually lower than full cash price. A reasonable sequence is:

1. Ask your insurer's specialty pharmacy or PBM in writing whether resmetirom is on formulary, what tier, and what prior authorization documentation is required.
2. Have your prescriber document fibrosis staging (biopsy or a validated noninvasive score), a trial or documented ineligibility for lifestyle intervention over a meaningful period, and specialist involvement if the plan requires it.
3. If denied, file an internal appeal citing your specific fibrosis stage and diagnostic evidence. If the internal appeal fails, Iowa residents can request an independent external review through the Iowa Insurance Division.
4. If approved with a copay, apply for manufacturer copay assistance before the first fill, since assistance programs typically require enrollment before or at the point of sale rather than as a reimbursement after the fact.

Should you consider a compounded version instead?

Only after confirming, with your prescriber, that a specific and documented clinical reason exists for compounding rather than dispensing the FDA-approved tablet. If the sole reason is cost, discuss instead whether commercial insurance appeal, manufacturer assistance, or a charitable foundation grant can close the gap, since those routes preserve access to the FDA-reviewed formulation with its established manufacturing quality controls. If a compounding pharmacy is used, verify current Iowa licensure through the Iowa Board of Pharmacy and ask whether the facility carries independent accreditation, such as through ACHC's compounding pharmacy program, and what beyond-use date and potency testing apply to the specific preparation.

Telehealth prescribing in Iowa

Iowa allows telehealth prescribing generally, and a physician holding an active Iowa license, including one obtained through the Interstate Medical Licensure Compact, can prescribe resmetirom via video visit. The diagnostic workup needed to confirm F2-F3 fibrosis (liver biopsy, FibroScan, or a validated noninvasive score) typically still requires an in-person visit to a facility with the right equipment, even when the prescribing visit itself is virtual. Because MASH pharmacotherapy is a specialist-guided decision, involving a hepatologist or gastroenterologist, in person or through telehealth, is the more relevant standard-of-care question than whether the visit format itself is virtual.

Clinical background on resmetirom

MASH with fibrosis was, before 2024, a condition without an FDA-approved drug therapy; management relied on weight loss, exercise, and off-label vitamin E or pioglitazone in appropriate patients. Resmetirom's approval was based on a large phase 3 randomized trial showing that a meaningfully higher proportion of patients on the 100 mg dose achieved fibrosis improvement and NASH resolution on repeat liver biopsy compared with placebo. Readers who want exact percentage results and confidence intervals should review the current FDA label directly, since reproducing precise trial statistics here without a verified primary-source citation risks passing along a transcription error. The FDA label also describes thyroid function monitoring, since resmetirom can lower TSH, and gastrointestinal side effects (diarrhea and nausea) as the most commonly reported adverse events in the trial population; individual dosing and monitoring decisions should be made with a prescriber, not from this article.

The confirmatory outcomes trial required for full approval has not yet reported results as of this writing, which is why some payers, including state Medicaid programs, have been cautious about formulary placement. This is a genuine open question, not a settled one, and it is the main reason Iowa Medicaid status and some commercial payer policies remain unstable and worth re-checking at the time you need the drug.

Verification checklist: stable facts versus facts you must re-check today

Use this before making a coverage or payment decision. Column one lists facts that come from federal regulation or clinical trial design and change slowly. Column two lists facts that are state-, insurer-, or pharmacy-specific and can change without notice.

If you cannot check a volatile-column item on the date you need to fill a prescription, treat any number you have as an estimate, not a quote.

When to seek urgent care instead of adjusting a resmetirom prescription

Resmetirom is a chronic-disease medication, and cost or coverage problems are not medical emergencies. However, contact your prescriber or seek urgent evaluation for new jaundice, severe abdominal pain, confusion, unusual bleeding or bruising, or signs of a severe allergic reaction. Do not stop or change a resmetirom dose to manage cost without talking to your prescriber first, since fibrosis-stage MASH treatment decisions should not be made unilaterally based on price alone.